HK inno.N Corporation (KOSDAQ:195940)

Market Cap	1.46T
Revenue (ttm)	839.63B
Net Income (ttm)	41.49B
Shares Out	28.33M
EPS (ttm)	1,451.65
PE Ratio	35.48
Forward PE	16.09
Dividend	350.00 (0.68%)
Ex-Dividend Date	n/a

Volume	137,759
Average Volume	217,009
Open	51,400
Previous Close	51,500
Day's Range	51,100 - 52,400
52-Week Range	31,650 - 54,200
Beta	0.63
RSI	55.46
Earnings Date	Feb 11, 2026

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,695
• Stock Exchange: KOSDAQ
• Ticker Symbol: 195940

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.